A safety trial of high dose glyceryl triacetate for Canavan disease. (Q50264960)

28 February 2018

title

A safety trial of high dose glyceryl triacetate for Canavan disease. (English)

1 reference

28 February 2018

4

Avraham Steinberg

1 reference

28 February 2018

9

Gheona Altarescu

1 reference

28 February 2018

author name string

Reeval Segel

1

1 reference

28 February 2018

Yair Anikster

2

1 reference

28 February 2018

Shoshana Zevin

3

1 reference

28 February 2018

William A Gahl

5

1 reference

28 February 2018

Drora Fisher

6

1 reference

28 February 2018

Orna Staretz-Chacham

7

1 reference

28 February 2018

Ari Zimran

8

1 reference

28 February 2018

publication date

15 March 2011

1 reference

28 February 2018

Molecular Genetics and Metabolism

published in

1 reference

28 February 2018

volume

103

1 reference

28 February 2018

issue

3

1 reference

28 February 2018

page(s)

203-206

1 reference

28 February 2018

The clinical course of Canavan disease.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.03.012

Canavan disease: from spongy degeneration to molecular analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.03.012

N-acetylaspartic aciduria due to aspartoacylase deficiency--a new aetiology of childhood leukodystrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.03.012

N-acetylaspartate as an acetyl source in the nervous system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.03.012

N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.03.012

Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.03.012

Progress toward acetate supplementation therapy for Canavan disease: glyceryl triacetate administration increases acetate, but not N-acetylaspartate, levels in brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.03.012

Effect of parenteral administration of short-chain triglycerides on leucine metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.03.012

Glyceryl triacetate for Canavan disease: a low-dose trial in infants and evaluation of a higher dose for toxicity in the tremor rat model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.03.012

Accumulation of N-acetyl-L-aspartate in the brain of the tremor rat, a mutant exhibiting absence-like seizure and spongiform degeneration in the central nervous system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.03.012

Metabolic acetate therapy improves phenotype in the tremor rat model of Canavan disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.03.012

Esterase inhibition by grapefruit juice flavonoids leading to a new drug interaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.03.012

10.1016/J.YMGME.2011.03.012

7 January 2021

Identifiers

DOI

1 reference

28 February 2018

1 reference

28 February 2018